CIK 0001782223
- Emerging growth company
Pyxis Oncology, Inc.
Sign in to watch- Ticker
- PYXS
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 831160910
- Phone
- +1 617-221-9059
- Business address
- 321 HARRISON AVENUE, BOSTON, MA, 02118
- 3 Insider Initial Statement of Ownership
- 4 Derivatives Options or other derivatives
- 3 Insider Initial Statement of Ownership
- 3 Insider Initial Statement of Ownership
- 4 Insider Changes in Ownership
- 3 Insider Initial Statement of Ownership
- 4 Open-market sale Former Director sold 1,745,761 shares at $3.05 ($5,324,571)
- 4 Grant or award Chief Financial Officer acquired 93,493 shares (grant or award)
- 4 Grant or award Chief Medical Officer acquired 115,931 shares (grant or award)
- 4 Grant or award Chief Executive Officer acquired 315,273 shares (grant or award)
- 4 Grant or award Director acquired 66,831 shares (grant or award)
- 4 Grant or award Chief Medical Officer acquired 306,930 shares (grant or award)
- 4 Grant or award Chief Executive Officer acquired 742,574 shares (grant or award)
- 4 Grant or award Director acquired 66,831 shares (grant or award)
- 4 Grant or award Director acquired 66,831 shares (grant or award)
- 4 Grant or award Director acquired 66,831 shares (grant or award)
- 4 Grant or award Chief Financial Officer acquired 247,524 shares (grant or award)
- 4 Grant or award Director acquired 66,831 shares (grant or award)
- 4 Open-market buy Director bought 10,000 shares at $9.39 ($93,885)
- 4 Derivatives Options or other derivatives
Page 5 of 7 · 126 filings